Journal
Clinical Cancer Research
Publication Date
7-5-2023
Volume
29
Issue
13
First Page
2466
Last Page
2479
Document Type
Open Access Publication
DOI
10.1158/1078-0432.CCR-22-3335
Rights and Permissions
Compadre AJ, van Biljon LN, Valentine MC, Llop-Guevara A, Graham E, Fashemi B, Herencia-Ropero A, Kotnik EN, Cooper I, Harrington SP, Kuroki LM, McCourt CK, Hagemann AR, Thaker PH, Mutch DG, Powell MA, Sun L, Mosammaparast N, Serra V, Zhao P, Lomonosova E, Khabele D, Mullen MM. RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer. Clin Cancer Res. 2023 Jul 5;29(13):2466-2479. doi: 10.1158/1078-0432.CCR-22-3335. ©2023 The Authors; Published by the American Association for Cancer Research This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
Recommended Citation
Compadre, Amanda J; van Biljon, Lillian N; Valentine, Mark C; Graham, Emily; Fashemi, Bisiayo; Kotnik, Emilee N; Cooper, Isaac; Kuroki, Lindsay M; McCourt, Carolyn K; Hagemann, Andrea R; Thaker, Premal H; Mutch, David G; Powell, Matthew A; Sun, Lulu; Mosammaparast, Nima; Zhao, Peinan; Lomonosova, Elena; Khabele, Dineo; Mullen, Mary M; and et al., "RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer." Clinical Cancer Research. 29, 13. 2466 - 2479. (2023).
https://digitalcommons.wustl.edu/oa_4/3152
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
